Dectrocel, a health-tech startup developing AI-powered diagnostic solutions, has raised Rs 4 crore in a funding round led by IAN Group-powered BioAngels along with participation from PadUp Ventures and Vinners. Key investors from IAN in this round include Nitin Zamre, Samir Kalia, and Mitesh Shah.
The proceeds will be used to scale its commercial operations across India, enhance self-learning foundational multimodal AI technology, expand into international markets, and accelerate the launch of its upcoming AI Tools in CT /MRI/PET-CT and HPB diagnostic modules, Dectrocel said in a press release.
Co-founded in 2020 by Ankit Shukla, Saumya Shukla, and Nikhil Mishra, Dectrocel is a health-tech company developing AI-powered diagnostic solutions for respiratory and hepato-pancreatico-biliary (HPB) diseases. Its flagship product, DecXpert, is one of only three AI-based diagnostic tools approved for clinical use in India by CDSCO, delivering chest X-ray and CT-scan interpretations and claims that it is 10x faster with 98% accuracy.
According to the Lucknow-based company, DecXpert bridges the critical diagnostic gap caused by India’s acute shortage of radiologists (1:125,000 ratio), particularly in tier-2 and smaller cities, where diagnosis delays of 7-10 days and error rates of 25-40% are common.
“We’re not just building AI diagnostic tools – we’re saving lives by ensuring that a patient in a tier-3 city gets the same quality chest X-ray/ CT /MRI/PET-CT Scan interpretation as someone in a metro hospital. Our 40.1% improvement in missed case detection, validated in Nature Scientific, proves that AI can be the great equalizer in healthcare access,” Ankit Shukla, founder & technical director, Dectrocel
Dectrocel plans to expand its commercial deployment of DecXpert across OEM partner networks, penetrate India’s Rs 1,000 crore digital X-ray market, and establish an initial presence in Southeast Asia. The company is also working on product diversification with new diagnostic modules for CT/MRI/ PET-CT scans and HPB disease Modules, and enhancing AI capabilities for broader pathology detection and self-learning adaptability.
